SCHEMBL141041

SCHEMBL141041

CC(=O)Nc1cc(Oc2ccc(N(C(=O)C3(C(N)=O)CC3)c3ccc(F)cc3)c(F)c2)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.44
MAPK13 O15264 3/20 0.42
MET P08581 6/20 0.41
KDR P35968 5/20 0.41
NTRK1 P04629 2/20 0.41
ABL1 P00519 2/20 0.41
EPHB6 O15197 1/20 0.41
RIPK2 O43353 1/20 0.41
LCK P06239 1/20 0.41
LYN P07948 1/20 0.41
RET P07949 1/20 0.41
HCK P08631 1/20 0.41
PDGFRB P09619 1/20 0.41
BCR P11274 1/20 0.41
EPHA2 P29317 1/20 0.41
EPHB2 P29323 1/20 0.41
FLT3 P36888 1/20 0.41
ABL2 P42684 1/20 0.41
FRK P42685 1/20 0.41
LIMK1 P53667 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL138397 0.90 KDR (0.49) MAPK14MAPK13METKDRNTRK1
SCHEMBL2257055 0.88 KDR (0.46) MAPK14MAPK13METKDRNTRK1
SCHEMBL2251925 0.88 MET (0.48) MAPK14METKDRNTRK1ABL1
SCHEMBL2250647 0.88 MET (0.48) MAPK14METKDRNTRK1ABL1
SCHEMBL141396 0.88 MET (0.43) MAPK14METKDRNTRK1RET
SCHEMBL2251525 0.87 MET (0.55) MAPK14METKDRNTRK1ABL1
Hydrochloric Acid SCHEMBL3554728 0.87 MET (0.48) MAPK14METKDRNTRK1ABL1
SCHEMBL2250948 0.87 KDR (0.46) MAPK14METKDRNTRK1ABL1
SCHEMBL2250798 0.86 KDR (0.46) MAPK14METKDRNTRK1ABL1
SCHEMBL2252404 0.86 AXL (0.39) MAPK14METKDRNTRK1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140194405-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-07-10 US disclosed
EP-2563362-B1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES DECIPHERA PHARMACEUTICALS LLC (US) 2014-03-12 EP disclosed
US-8637672-B2 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-01-28 US disclosed
US-20120322834-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-12-20 US disclosed
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHAMACEUTICALS, LLC (US) 2012-10-04 US disclosed
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194405-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPK14 863/4885MAPK13 1355/4885MET 2169/4885
US-20120252849-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPK14 863/4885MAPK13 1355/4885MET 2169/4885
US-20120322834-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPK14 863/4885MAPK13 1355/4885MET 2169/4885
US-20120058985-A1 CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES TP53, RCC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPK14 863/4885MAPK13 1355/4885MET 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.